<DOC>
	<DOC>NCT01587079</DOC>
	<brief_summary>The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD</brief_summary>
	<brief_title>Glycopyrrolate/Formoterol Fumarate MDI Compared With SpirivaÂ® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Key Signed written informed consent 40 80 years of age Clinical history of COPD with airflow limitation that is not fully reversible Females of nonchild bearing potential or females of child bearing potential with negative pregnancy test and acceptable contraceptive methods Current/former smokers with at least a 10 packyear history of cigarette smoking A measured postbronchodilator FEV1/FVC ratio of &lt; or = 0.70 A measured postbronchodilator FEV1 &gt; or = 750ml or 30% predicted and &lt; or = 80% of predicted normal values Able to change COPD treatment as required by protocol Key Women who are pregnant or lactating Primary diagnosis of asthma Alpha1 antitrypsin deficiency as the cause of COPD Active pulmonary diseases Prior lung volume reduction surgery Abnormal chest Xray not due to the presence of COPD Hospitalized due to poorly controlled COPD within 3 months of Screening Clinically significant medical conditions that preclude participation in the study (e.g. clinically significant abnormal ECG, uncontrolled hypertension, glaucoma, symptomatic prostatic hypertrophy) Cancer that has not been in complete remission for at least 5 years Treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives Other inclusion/exclusion criteria as defined in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>COPD</keyword>
</DOC>